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The prevalenceof allergic diseasesis rapidly increasing
(Bauchau and Durham 2004). Allergen-SIT, which is
based on the administration of the disease eliciting
allergens or derivatives, is the only treatment which
leads to a life-long tolerance towards previously
disease-causing allergens due to restoration of normal
immunity against allergens. The treatment has been
shown to be particularly beneﬁcial in allergic rhinitis,
mild and moderate asthma and insect venom
hypersensitivity.
Whole aqueous extracts of natural allergen source
materials such as pollens, mites, moulds and animal
epithelia are the basis for therapeutic preparations that
are currently used in clinical practice. The extracts are
standardized in terms of total allergenic activity, or
potency, and possibly the concentration of one
individual major allergen, whilst product consistency
is assessed in terms of protein and allergen proﬁles
determined by various techniques including electro-
phoresis and immunoblotting. An extract may contain
numerous proteins only some of which are allergens.
The composition is determined to a large extent by the
qualityoftherawmaterialandthemethodofextraction
and puriﬁcation. Raw materials are provided by
certiﬁed suppliers and produced under controlled
conditions, but nevertheless there are differences.
In addition many extracts derived from natural
materials contain endotoxin (Trivedi et al. 2003).
The use of recombinant DNA technology appears
to provide a realistic means of achieving improve-
ments aiming at obtaining of more precisely deﬁned
preparations. This technology also provides the
possibility to create allergen derivatives with reduced
IgE-reactivity, that is to say hypoallergenic molecules
that have a reduced risk for inducing undesirable
allergic reactions during the course of immunother-
apy, but which retain their therapeutic activity.
Numerous allergens have now been cloned for
research purposes, but as yet only a few have been
developed to the stage at which they can be used in
clinical studies.
Production of recombinant allergens
Once an allergen source has been identiﬁed, messen-
ger-RNA (mRNA) is isolated and used as a template
to synthesise complementary-DNA (cDNA).
IgE-immunoscreening of cDNA libraries can then be
used to select those cDNA encoding allergens that
most closely resemble their natural counterparts.
Allergen speciﬁc monoclonal antibodies can also be
used. Alternatively DNA-based screening techniques,
such as polymerase chain reaction ampliﬁcation,
which relies on the use of oligonucleotide primers
designed on the basis of known amino acid sequence
data for the allergen, may be used. Phage surface
display technology has also been used to great
advantage to identify a number of allergens. A physical
linkage between the gene product and its cDNA
facilitates isolation of the speciﬁc cDNA from large
libraries (Crameri et al. 1994, Crameri 1998).
The next step is to insert the cDNA into a suitable
vector (viral and plasmid DNA), which enables it to be
expressed and produced in a suitable host organism.
Bacterial host organisms, such as Escherichia coli,
produce the recombinant proteins without post-
translational modiﬁcation, and in many cases it is
possible to obtain the allergens with reactivity
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folding and post-translational modiﬁcations, includ-
ing glycosylation, become an issue then a eukaryotic
expression system such as the yeast Pichia pastoris,
baculovirus in host insect cells, and various plants
including the tobacco plant Nicotiana benthamiana
(Wagner et al. 2004) and barley (Horvath et al. 2000)
may be used. However these do not necessarily
introduce glycosylation that is comparable with that of
the natural glycoprotein, and one example for this is
the expression of the house dust mite allergen Der p 1
in P. pastoris which results in inappropriate hyper-
glycosylation (Jacquet et al. 2002).
Following a fermentation process and induction of
gene expression the heterologous recombinant protein
is recovered from the cell culture and puriﬁed using
appropriate chromatographic methods. Optimal
production conditions must be determined for each
protein in order to ensure that correct and reprodu-
cible secondary and tertiary structures are achieved,
but once these are established the use of modern
technology enables pure protein to be produced with
consistent pharmaceutical quality (Cromwell et al.
2004, Batard et al. 2005).
The so-called “wild type” recombinant allergens
exhibiting IgE-reactivity comparable with that of the
natural allergen are particularly suitable for diagnostic
applications and may also substitute for natural
allergens used in speciﬁc immunotherapy. The success
of the latter is, however, dependent primarily on the
T-cell reactivity and immunogenicity of the protein.
The allergen Phl p 1 from Timothy grass is naturally
glycosylated, but the presence of the carbohydrate
moiety appears not to be important for IgE-reactivity.
When compared for their ability to activate peripheral
blood basophils and T-cell lines from grass pollen
allergic subjects the puriﬁed natural molecule and a
recombinant non-glycosylated form obtained by
expression in E. coli gave essentially identical results
(Figure 1).
The production of recombinant proteins depends
initially on the creation of a master cell bank
incorporating a DNA construct including the
expression vector together with the cDNA encoding
the protein. This is the starting point for all routine
production batches. Each production run starts with
an aliquot of cells derived from the one cell bank thus
ensuring that the identical protein is always produced.
The quality control of the recombinant proteins is
undertaken using an array of analytical methods.
Identity is conﬁrmed by reactivity with speciﬁc
antibodies on immunoblot, peptide ﬁngerprinting
and N-terminal amino acid analysis. Purity is
determined by sodium dodecyl sulfate (SDS) poly-
acrylamide gel electrophoresis (PAGE), native PAGE
(Suck et al. 2003), both in conjunction with protein
staining, size exclusion high performance liquid
chromatography (HPLC) and reverse phase-HPLC,
taking account of peak symmetry. Allergen concen-
tration is expressed in terms of absolute protein
concentration determined from the UV absorption at
280nm and the speciﬁc extinction coefﬁcient of the
particular protein, and conﬁrmed as appropriate by
speciﬁc antibody immunoassays and integrated
HPLC peak areas. It is important to be able to
determine the potency, and with natural allergen
equivalents this can be best achieved by measuring
IgE-binding activity in an inhibition immunoassay.
The use of such a potency measure in respect of
preparations for immunotherapy assumes a relation-
ship between IgE-reactivity and antigenicity.
Levels of possible contaminants, including endo-
toxin and host cell proteins, are also measured.
Endotoxin (lipopolysaccharide, LPS) is derived from
the outer membrane of Gram-negative bacteria and
canbedetectedinmanyallergenextracts(Trivedietal.
2003). This is a potential problem for recombinant
allergens expressed in the gram-negative bacteria E.
coli, but the chromatographic puriﬁcation steps for the
protein can be designed to ensure that it is rendered
effectively free of contamination.
Composition of vaccine
One concept that has propagated is that of patient
tailored immunotherapy (Valenta et al. 1999). The
availability of pure recombinant allergens will make it
possible to perform component-resolved diagnosis
and to produce IgE reactivity proﬁles for individual
patients. However, the more immediate prospect is for
the introduction of standard combinations of allergens
from one source, or in some cases single allergens.
One allergen or allergen derivative will sufﬁce for an
effective vaccine in cat (Fel d 1) and birch (Bet v 1)
sensitized subjects. The rationale being that one major
allergen dominates and accounts for most or all of the
speciﬁc IgE directed against the one sensitizing agent.
However, in pollen or mite sensitizations the
sensitization patterns are more complex.
Grass pollen has 11 different allergens that have
been identiﬁed and characterized in detail and some of
these are known to occur as several different isoforms.
Only some of these allergens have major general
importance being associated with a high prevalence of
sensitization in the grass pollen allergic population
and together accounting for a large part of the speciﬁc
IgE directed against the whole pollen extract.
The grass Phleum pratense is a member of the
sub-family Pooideae, which in turn belongs to the
family Poaceae. It shows very substantial cross-
reactivity with other members of the sub-family
(Andersson and Lidholm 2003) and can therefore,
be considered as representative of grasses found in
temperate regions.
The group 1 and 5 allergens are strong candidates
for inclusion in a therapeutic vaccine. In excess of 90%
M. Jutel & O. Cromwell 390of grass pollen allergic subjects react to group 1 and up
to 85% to group 5 (Andersson and Lidholm 2003;
Suphioglu 2000). There are two isoallergens of the
Timothy grass pollen allergen Phl p 5, the principal
difference between which is that two 14/15 amino acid
sequences are missing from the N-terminal half of Phl
p 5b as compared with Phl p 5a. The molecules show
extensive homology, and although there is a very high
degree of IgE antibody cross-reactivity, there are
nevertheless some immunological differences in terms
of T cell reactivity that may justify the inclusion of
both isoallergens in a vaccine. The allergens Phl p 2
and 6 show prevalences of sensitization in the ranges
40–60 and 60–70%, respectively, and are thus
Figure 1. Comparison of natural glycosylated and recombinant non-glycosylated Phl p 1. Peripheral blood mononuclear cells from grass
pollen allergic subjects were incubated with various concentrations of the allergens or the diluent solution. Basophil activation was measured
by ﬂuorescence activated ﬂow cytometry in terms of expression of the surface marker CD203c. B. Lymphocyte proliferation, expressed as a
stimulation index (SI) was determined in terms of
3H-thymidine incorporation by T-cell lines (TCL) derived from grass pollen allergic
subjects. White bars natural glycosylated Phl p 1, black bars non-glycosylated recombinant Phl p 1.
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of grass pollen sensitized subjects may have IgE
antibodies directed to the group 4 allergen, the
concentrations are relatively low compared with those
speciﬁc for Phl p 1 and 5, as too is speciﬁc skin test
reactivity. Further allergens including Phl p 7, 10, 11
and 12 are classiﬁed as minor allergens and are
therefore not strong contenders for inclusion in a
vaccine. Prevalence of sensitization to the calcium
binding protein designated as Phl p 7 is only about
10% (Rossi et al. 2001) and subjects reacting to Phl p
10 (cytochrome c) are seldomly found (Andersson
and Lidholm 2003). Both Phl p 11 (proﬁlin) and 13
are glycosylated and a substantial part of the
IgE-reactivity appears to involve cross-reactive
carbohydrate determinants (CCD).
It is not realistic to represent all allergens from a
particular source in the vaccine. It is reasonable to
include the group 1 and 5 allergens and these may be
supplemented by other relatively important allergens
such as group 2 and 6, and possibly 4. A study
conducted using two puriﬁed natural allergens of P.
pratense, which were subsequently identiﬁed as Phl p 5
and 6, proved to be signiﬁcantly less clinically effective
than a partially puriﬁed whole allergen extract, and
one can now speculate that this might have been
attributable to the lack of Phl p 1 (Osterballe 1980,
Osterballe et al. 1981).
Results of clinical study
Separate aluminum hydroxide adsorbates of the
recombinant allergens Phl p 1, 2, 5a, 5b and 6 were
prepared and mixed together to create a therapeutic
vaccine, with approximately equimolar amounts of
the individual allergens. This mixture of allergens
accounts for a substantial proportion of the speciﬁc
IgE sensitization developed against grass pollen and,
therefore, it is realistic to expect that it can be effective
against a substantial part of the symptoms.
A double-blind placebo-controlled clinical trial was
undertaken with 62 grass pollen allergic patients
suffering from rhinoconjunctivitis with or without
asthma (Jutel et al. 2005). The recombinant allergen
adsorbate was administered in subcutaneous injec-
tions of increasing concentrations at 7-day intervals
prior to the pollen season in 2002, starting with
0.02mg total protein, followed by 0.16mg and then
doubling to 40mg total protein (0.8ml). The
maximum dose contained 10mg Phlp1, 5mg Phlp2,
10mgP h l p 5 a ,1 0 mgP h l p 5 ba n d5 mgP h l p 6 .
Maintenance injections were continued until after
the subsequent pollen season with a 50% reduction
during each pollen season. The median cumulative
dose was 490mg total protein, corresponding to
122.5mg each of Phl p 1, 5a and 5b, and 61.25mgo f
Phl p 2 and 6.
A symptom–medication score was the primary
outcome measure to assess efﬁcacy. Subjects kept
diaries for three months over each pollen season to
record nature and severity of eye, nose and chest
symptoms, and type and dose of any medication.
Intensity of symptoms was documented as 0 ¼ no
symptoms; 1 ¼ mild; 2 ¼ moderate and 3 ¼ severe.
Thesamerescuemedicationwasavailabletoallsubjects
and usage was scored taking account of pharmacoki-
netic and pharmacodynamic characteristics. A per
protocol analysis included 24 active treatment and 25
placebo patients. A combined symptom–medication
score adopted as primary end-point showed a 39%
improvement in the active treatment group relative to
placebo (p ¼ 0.041). Symptoms alone improved by
37% (p ¼ 0.015) and the use of symptomatic medi-
cation decreased by 36.5% relative to placebo.
A validated rhinitis quality of life questionnaire
(RQLQ) was a secondary end-point (Juniper and
Guyatt 1991). Questionnaires were completed every
two weeks during the pollen seasons and the
questionnaire following the maximum pollen count
was used for analysis. Beneﬁts were registered for
those subjects on active treatment during the ﬁrst
pollen season. However, the per protocol evaluation
during the second pollen season showed even greater
differences between active and placebo treatment with
an overall signiﬁcant beneﬁt (p ¼ 0.024), providing
further evidence of clinical efﬁcacy. Signiﬁcant effects
were seen in ﬁve of seven domains tested (Figure 2).
The level of clinically relevant improvement for
individual subjects is considered to be 0.5, and the
mean between groups differences that were judged
statistically signiﬁcant were all considerably in excess
Figure 2. RQLQ for subjects undergoing immunotherapy with a
mixture of ﬁve recombinant P . pratense pollen allergens. Bars show
differences between active and placebo treatment groups in pollen
seasons during the ﬁrst and second years of the study, 2002 (gray)
and 2003 (black), respectively. Questionnaires completed
immediately following the maximum pollen count were used for
analysis. Mann–Whitney U-test and p values for the 2003 season.
Reprinted from J Allergy Clin Immunol, 116(3), Jutel M, Jaeger L,
Suck R, Meyer H, Fiebig H, Cromwell O. 2005, Allergen-speciﬁc
immunotherapy with recombinant grass pollen allergens, 608–613,
with permission from American Academy of Allergy Asthma and
Immunology.
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performed prior to therapy (inclusion criterion) and at
the end of the study using a standardized 6-grass
allergen extract. The concentration was increased in
half-log steps starting with 5BU/ml until a positive
reaction was obtained or a maximum concentration
of 5000BU/ml (0.18mg group 5 allergen/drop) was
reached. A favorable trend was observed (p ¼ 0.081)
with an increase in the threshold dose in favor of
treatment with the active preparation. The failure to
achieve a signiﬁcant result was most likely attributable
to the small numbers of patients.
Activetreatmentinducedhighlysigniﬁcantincreases
in both IgG1 and IgG4 grass pollen speciﬁc antibody
concentrations together with a signiﬁcant decrease in
IgE (Figure 3). IgG1 increased approximately 60-fold,
peaking during the ﬁrst 12 months of the study. IgG4
showed a continuing upward trend, achieving an
approximately 4000-fold increase by the end of
treatment. Speciﬁc IgE levels were not signiﬁcantly
different between groups at the beginning of the study,
but thereafter the active treatment group showed a
downward trend with values signiﬁcantly less than
baseline.FoursubjectsineachgrouphadnoPhlp5a/b
speciﬁc IgE prior to the study, but reacted to Phl p 1
andothergrasspollenallergens.Noneofthesesubjects
developed Phl p 5a/b IgE antibodies during the study,
although the four subjects receiving active treatment
developed strong IgG4 and IgG1 Phl p 5a/b responses
consistent with induction of a protective immune
response. This observation obviously needs to be
substantiatedanditwillalsobeofinteresttolookatthe
prophylactic effects of the treatment in guarding
against the development of new sensitizations.
Treatment related adverse events were seen in
association with 78 injections (10.7%) in the active
treatment group and 44 injections (5.9%) in the
placebo group. Local reactions involving erythema
and swelling in the vicinity of the injection site, with or
without pruritus, accounted for nearly all these
reactions. Single systemic reactions were seen in
seven active treatment and two placebo subjects, the
former including general urticaria (two cases), local
urticaria (two cases), dyspnea (one case), rhinocon-
junctivitis (one case) and one case of asthma two days
following the injection. All these subjects continued
treatment without further problems and it was
concluded that the preparation showed a favorable
safety when compared with ﬁndings from other
immunotherapy studies.
Conclusion
Recombinant DNA technology has delivered the
prospect of a new generation of preparations for
allergen speciﬁc immunotherapy. The ﬁrst clinical
studies with recombinant allergens have yielded very
encouraging results, which suggest that there is a very
good chance that such preparations will become
available for use in the routine management of allergic
disease.
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